Modulating the tumor microenvironment through chemokine disruption

Roisin McGuigan, Commissioning Editor, Immuno-Oncology Insights, speaks to
Avital Barak, VP of Clinical Development and Medical Affairs, TME Pharma, about chemokine inhibition as an approach to modulating the TME, current tools and approaches to tackling the tumor microenvironment, and the explosion of innovation in this space.

Please enter your email to access content Read now